Table 3.
Antimicrobial sensitivity and resistance pattern of bacteria isolated from chronic suppurative media patients
| Organism | S/R n (%) | AMP, n (%) | COT, n (%) | CIP, n (%) | E, n (%) | PIP, n (%) | GEN, n (%) | AK, n (%) | LEV, n (%) | CF, n (%) | CBP, n (%) | AMC, n (%) | CFZ, n (%) | KM, n (%) | VM, n (%) | CL, n (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PA | S | – | – | – | – | 41 (91.1) | 32 (71.11) | 32 (71.11) | – | 23 (51.11) | 18 (40) | – | – | – | – | – |
| R | – | – | – | – | 4 (8.89) | 13 (28.89) | 13 (28.89) | – | 22 (48.89) | 27 (60) | – | – | – | – | – | |
| SA | S | 21 (55.26) | 24 (63.15) | 8 (21.1) | 27 (71.05) | – | – | – | – | – | – | 17 (44.74) | – | – | – | – |
| R | 17 (44.74) | 14 (36.85) | 30 (78.9) | 11 (28.95) | – | – | – | – | – | – | 21 (55.26) | – | – | – | – | |
| MRSA | S | 3 (50) | 4 (66.67) | 1 (16.7) | 5 (83.3) | – | – | – | – | – | – | 3 (50) | – | – | – | – |
| R | 3 (50) | 2 (33.33) | 5 (83.3) | 1 (16.7) | – | – | – | – | – | – | 3 (50) | – | – | – | – | |
| CF | S | 1 (25) | 4 (100) | 4 (100) | – | 4 (100) | 3 (75) | – | 4 (100) | – | – | – | ||||
| R | 3 (75) | 0 | 0 | – | 0 | 1 (25) | – | 0 | – | – | – | |||||
| PM | S | – | – | – | – | 3 (100) | 2 (66.6) | 2 (66.6) | – | 1 (33.4) | 2 (66.6) | – | – | – | – | – |
| R | – | – | – | – | 0.00 | 1 (33.4) | 1 (33.4) | – | 2 (66.6) | 1 (33.4) | – | – | – | – | – | |
| EC | S | 1 (33.3) | 1 (33.3) | 1 (33.3) | – | 1 (33.3) | 3 (100) | – | – | – | – | 0.00 | – | – | – | |
| R | 2 (66.7) | 2 (66.7) | 2 (66.7) | – | 2 (66.7) | 0 | – | – | – | – | 3 (100) | – | – | – | ||
| KP | S | 1 (50) | 1 (50) | 1 (50) | – | – | – | 0 | – | 1 (50) | 0 | – | – | – | ||
| R | 1 (50) | 1 (50) | 1 (50) | – | – | – | 2 (100) | – | 1 (50) | 2 (100) | – | – | – | |||
| A | S | – | – | – | – | 1 (100) | 1 (100) | 1 (100) | – | 0 | 1 (100) | – | – | – | – | – |
| R | – | – | – | – | 0 | 0 | 0 | – | 1 (100) | 0 | – | – | – | – | – | |
| CK | S | 1 (100) | – | – | – | 1 (100) | 1 (100) | – | – | – | 1 (100) | – | 0 | – | – | – |
| R | 0 | – | – | – | 0 | 0 | – | 0 | – | 1 (100) | – | – | – | |||
| SP | S | – | – | – | 0 | 1 (100) | 0 | 1 (100) | 0 | – | – | – | – | |||
| R | – | – | – | 1 (100) | – | 0 | – | 1 (100) | 0 | 1 (100) | – | – | – | – | ||
| CONS | S | 1 (100) | 0 | 0 | 0 | – | – | – | – | – | – | 0 | – | – | – | – |
| R | 0 | 1 (100) | 1 (100) | 1 (100) | – | – | – | – | – | – | 1 (100) | – | – | – | – | |
| PI | S | – | – | – | – | – | – | – | – | – | – | – | – | 4 (80) | 1 (20) | 5 (100) |
| R | – | – | – | – | – | – | – | – | – | – | – | – | 1 (20) | 4 (80) | 0 | |
| BF | S | – | – | – | – | – | – | – | – | – | – | – | – | 2 (50) | 1 (25) | 2 (50) |
| R | – | – | – | – | – | – | – | – | – | – | – | – | 2 (50) | 3 (75) | 2 (50) | |
| PPM | S | – | – | – | – | – | – | – | – | – | – | – | – | 2 (100) | 0 | 0 |
| R | – | – | – | – | – | – | – | – | – | – | – | – | 0 | 2 (100) | 2 (100) |
S sensitive; R resistant
PA Pseudomonas aeuroginosa; SA Staphylococcus aureus; MRSA Methicillin resistant Staphylococcus aureus; CF Citrobacter freundii; PM Proteus mirabilis; EC Escherichia coli; KP Klebsiella pneumonia; A Acinetobacter; CK Citrobacter koseri; SP Streptococcus pneumonia; CONS Coagulase negative staphylococcus; PI Prevotella intermedia; BF: Bacteroides fragilis; PPM Porphyromonas
AMP ampicillin; COT cotrimoxazole; CIP ciprofloxacin; E erythromycin; PIP piperacillin; GEN gentamicin; AK amikacin; LEV levofloxacin; CF ceftriaxone; CBP carbpenicillin; AMC amoxiclave; CFZ ceftazidime; KM kanamycin; VM vancomycin; CL colistin